InnoCare Pharma Limited(SHSE:688428) added to Shanghai Stock Exchange Composite Index

InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.